{"filing":{"accession_number":"0000031791-26-000022","cik":"0000031791","ticker":"RVTY","company_name":"REVVITY, INC.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"pki-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/31791/000003179126000022/pki-20260804.htm"},"events":[{"id":23534,"run_id":21274,"accession_number":"0000031791-26-000022","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Revvity announced Q2 2026 financial results on August 4, 2026, disclosing revenue of $730 million, GAAP EPS of $0.48, and adjusted EPS of $1.41, along with raising full-year pro forma revenue guidance to $2.83–$2.86 billion.","company_name":"REVVITY, INC.","ticker":"RVTY","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":23786,"accession_number":"0000031791-26-000022","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Revvity announced its Q2 2026 financial results on August 4, 2026, disclosing revenue of $730 million, GAAP EPS of $0.48, and adjusted EPS of $1.41, along with full-year guidance raising forecasts to $2.83–$2.86 billion in pro forma revenue. The press release is furnished as Exhibit 99.1 and constitutes a standard quarterly earnings announcement under Item 2.02, which is material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:22:40.608852+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":23535,"run_id":21274,"accession_number":"0000031791-26-000022","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Revvity entered into a definitive agreement on July 31, 2026 to divest its Immunodiagnostics business in China for up to $200 million, subject to adjustments and closing conditions, with expected close by end of 2027. The divestiture represents approximately 6% of 2025 revenue.","company_name":"REVVITY, INC.","ticker":"RVTY","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":23787,"accession_number":"0000031791-26-000022","item_number":"8.01","item_title":"Other Events","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Revvity entered into a definitive agreement on July 31, 2026 to divest its Immunodiagnostics business in China (\"China IDX\") for up to $200 million, subject to adjustments and closing conditions. The transaction is expected to close by end of 2027. This is a material disposition of a business segment representing approximately 6% of 2025 revenue, disclosed under Item 8.01 with pro forma financial statements reflecting the probable sale.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:22:40.608852+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23786,"accession_number":"0000031791-26-000022","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Revvity announced its Q2 2026 financial results on August 4, 2026, disclosing revenue of $730 million, GAAP EPS of $0.48, and adjusted EPS of $1.41, along with full-year guidance raising forecasts to $2.83–$2.86 billion in pro forma revenue. The press release is furnished as Exhibit 99.1 and constitutes a standard quarterly earnings announcement under Item 2.02, which is material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:22:40.608852+00:00","company_name":"REVVITY, INC.","ticker":"RVTY","filing_date":"2026-08-04"},{"id":23787,"accession_number":"0000031791-26-000022","item_number":"8.01","item_title":"Other Events","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Revvity entered into a definitive agreement on July 31, 2026 to divest its Immunodiagnostics business in China (\"China IDX\") for up to $200 million, subject to adjustments and closing conditions. The transaction is expected to close by end of 2027. This is a material disposition of a business segment representing approximately 6% of 2025 revenue, disclosed under Item 8.01 with pro forma financial statements reflecting the probable sale.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:22:40.608852+00:00","company_name":"REVVITY, INC.","ticker":"RVTY","filing_date":"2026-08-04"}]}